New cancer clinical trial: Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Published on: March 26, 2018 at 12:00PM
Conditions:   Stage III Prostate Cancer;   Stage IIIA Prostate Cancer;   Stage IIIB Prostate Cancer;   Stage IIIC Prostate Cancer;   Stage IV Prostate Cancer;   Stage IVA Prostate Cancer;   Stage IVB Prostate Cancer
Interventions:   Biological: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Procedure: Radical Prostatectomy;   Biological: Anti-PD-1 Monoclonal Antibody REGN2810
Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Prostate Cancer Foundation;   Regeneron Pharmaceuticals
Not yet recruiting
https://ift.tt/2usQDRR